RBL2抗体

+ +

•  

   

     Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane: Lncap cell, Primary antibody: P04620(RBL2 Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 4 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P04620(RBL2 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain tissue using P04620(RBL2 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

The RBL2 antibody is designed to target Retinoblastoma-like protein 2 (RBL2), also known as p130. a member of the retinoblastoma (Rb) tumor suppressor protein family that includes pRb (p105), p107. and p130. These proteins play critical roles in cell cycle regulation, primarily by inhibiting the G1-to-S phase transition through interactions with E2F transcription factors. RBL2/p130. encoded by the *RBL2* gene, shares structural homology with other Rb family members, particularly in the conserved "pocket domain" responsible for binding viral oncoproteins and cellular partners. Unlike pRb, which is predominantly expressed in differentiating cells, RBL2/p130 is highly expressed in quiescent or terminally differentiated cells, where it forms repressive complexes with E2F4 or E2F5 to silence cell cycle-promoting genes.

Antibodies against RBL2 are widely used in research to study its expression, localization, and functional interactions in cellular contexts such as proliferation, differentiation, and apoptosis. Dysregulation of RBL2/p130 has been linked to various cancers, where loss or mutation contributes to uncontrolled cell growth. Additionally, RBL2/p130 is involved in developmental processes and cellular senescence. Researchers employ RBL2 antibodies in techniques like Western blotting, immunohistochemistry, and co-immunoprecipitation to explore its role in tumor suppression, its phosphorylation-dependent inactivation during cell cycle progression, and its interplay with oncogenic viruses. These studies provide insights into cancer mechanisms and potential therapeutic targets.